JP2013505937A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505937A5
JP2013505937A5 JP2012531012A JP2012531012A JP2013505937A5 JP 2013505937 A5 JP2013505937 A5 JP 2013505937A5 JP 2012531012 A JP2012531012 A JP 2012531012A JP 2012531012 A JP2012531012 A JP 2012531012A JP 2013505937 A5 JP2013505937 A5 JP 2013505937A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012531012A
Other languages
English (en)
Japanese (ja)
Other versions
JP5893561B2 (ja
JP2013505937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/049912 external-priority patent/WO2011038061A2/en
Publication of JP2013505937A publication Critical patent/JP2013505937A/ja
Publication of JP2013505937A5 publication Critical patent/JP2013505937A5/ja
Application granted granted Critical
Publication of JP5893561B2 publication Critical patent/JP5893561B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012531012A 2009-09-25 2010-09-23 新規npr−bアゴニスト Expired - Fee Related JP5893561B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
US61/245,960 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015086575A Division JP6211032B2 (ja) 2009-09-25 2015-04-21 新規npr−bアゴニスト

Publications (3)

Publication Number Publication Date
JP2013505937A JP2013505937A (ja) 2013-02-21
JP2013505937A5 true JP2013505937A5 (enExample) 2013-09-05
JP5893561B2 JP5893561B2 (ja) 2016-03-23

Family

ID=43781057

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012531012A Expired - Fee Related JP5893561B2 (ja) 2009-09-25 2010-09-23 新規npr−bアゴニスト
JP2015086575A Expired - Fee Related JP6211032B2 (ja) 2009-09-25 2015-04-21 新規npr−bアゴニスト
JP2017101128A Withdrawn JP2017137362A (ja) 2009-09-25 2017-05-22 新規npr−bアゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015086575A Expired - Fee Related JP6211032B2 (ja) 2009-09-25 2015-04-21 新規npr−bアゴニスト
JP2017101128A Withdrawn JP2017137362A (ja) 2009-09-25 2017-05-22 新規npr−bアゴニスト

Country Status (17)

Country Link
US (5) US8546523B2 (enExample)
EP (1) EP2480247B1 (enExample)
JP (3) JP5893561B2 (enExample)
KR (3) KR101768661B1 (enExample)
CN (2) CN102548574B (enExample)
AR (1) AR078445A1 (enExample)
AU (1) AU2010298256B2 (enExample)
BR (1) BR112012006579A2 (enExample)
CA (1) CA2773949C (enExample)
CL (2) CL2012000715A1 (enExample)
MX (3) MX354005B (enExample)
PH (1) PH12012500562A1 (enExample)
RU (3) RU2557290C2 (enExample)
TW (2) TWI625126B (enExample)
UY (1) UY32902A (enExample)
WO (1) WO2011038061A2 (enExample)
ZA (3) ZA201201630B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392892T3 (es) 2005-04-07 2012-12-14 Cardiopep Pharma Gmbh Uso de un péptido natriurético para tratar insuficiencia cardiaca
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
KR101768661B1 (ko) 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 신규한 npr-b 길항제
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
US20150045301A1 (en) * 2011-12-16 2015-02-12 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
EP2948165A2 (en) * 2013-01-25 2015-12-02 Cardiorentis Ltd. A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
JP2020505476A (ja) * 2017-02-01 2020-02-20 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 眼科障害の治療のための化合物および組成物
AU2019288296B2 (en) * 2018-06-19 2022-11-24 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a CNP compound, an NPR-B compound, a Tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
AU2019379808C1 (en) * 2018-11-16 2024-01-25 Arcus Biosciences, Inc. Inhibitors of ARG1 and/or ARG2
CA3184145A1 (en) * 2020-06-12 2021-12-16 Pharmain Corporation C-type natriuretic peptides and methods thereof in treating acute lung injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
AU2927889A (en) * 1987-12-24 1989-07-19 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
WO1990001940A1 (en) 1988-08-18 1990-03-08 California Biotechnology Inc. Atrial natriuretic peptide clearance inhibitors
US6833358B1 (en) 1998-09-28 2004-12-21 Santen Pharmaceutical Co., Ltd. Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006005140A2 (en) * 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
CA2625600A1 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
BRPI0709427A2 (pt) 2006-03-30 2011-07-12 Palatin Technologies Inc "construto cìclico, composição farmacêutica e uso de um composto
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
KR101768661B1 (ko) * 2009-09-25 2017-08-16 샤이어 오펀 테라피즈 게엠베하 신규한 npr-b 길항제
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists

Similar Documents

Publication Publication Date Title
JP2013505937A5 (enExample)
JP2012525416A5 (enExample)
JP2011026329A5 (enExample)
JP2011006413A5 (enExample)
JP2012031285A5 (enExample)
JP2013539946A5 (enExample)
JP2013531034A5 (enExample)
JP2012204203A5 (enExample)
JP2012524113A5 (enExample)
JP2013531018A5 (enExample)
JP2011214087A5 (enExample)
JP2012023335A5 (enExample)
JP2014505137A5 (enExample)
JP2010049241A5 (enExample)
JP2012011657A5 (enExample)
JP2013064178A5 (enExample)
JP2010166925A5 (enExample)
JP2011208181A5 (enExample)
JP2011207949A5 (enExample)
JP2012042569A5 (enExample)
JP2012011658A5 (enExample)
JP2012193264A5 (enExample)
JP2011146571A5 (enExample)
JP2012190699A5 (enExample)
JP2013503915A5 (enExample)